Clinical evidence on the safety of NMN released recently

Researchers from Keio University and Washington University published a new article on Endocrine Journal.

The safety of single dose at 100, 250, and 500 mg NMN was investigated in 10 Japanese men.

Clinical findings and parameters, and the pharmacokinetics of NMN metabolites were investigated for 5 h after each intervention.

The study concluded that the single oral administration of NMN was safe and effectively metabolized in healthy men without causing any significant deleterious effects. Thus, the oral administration of NMN was found to be feasible, implicating a potential therapeutic strategy to mitigate aging-related disorders in humans[1].

The study is just the start of a series of clinical studies on NMN and it proved NMN’s safety to some extent.

However, due to the lack of a control group and the small sample size, further studies will be needed. Besides, the safety of repeated-dose on humans remains to be confirmed.

The clinical study on UTHEVERTM would somehow further confirms NMN’s safety on repeated dose with placebo group. The sample size would be 66 which is more convincing.

Reference

1. Junichiro Irie, etc. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men, Endocine Journal, 2020, 67 (2), 153-160